SWK — Merger or Acquisition (August 2019)
21 slides from SWK's merger presentation, Aug 27, 2019
Slide 1: Acquisition of Enteris BioPharma
Acquisition of Enteris BioPharma Collaborative Approach to Life Science Financing
Slide 2: Forward-looking and Cautionary Statements
Forward - looking and Cautionary Statements Statements in this presentation that are not strictly historical, and any statements regarding events or developments that we be lieve or anticipate will or may occur in the future are "forward - looking" statements within the meaning of the federal securi
Slide 3: Agenda
Agenda Acquisition Highlights and Rationale Peptelligence ® Technology & Business Model Overview Internal 505(b)(2) Pipeline Enteris Financial Overview 3
Slide 4: Acquisition Highlights and Rationale
ACQUISITION HIGHLIGHTS AND RATIONALE
Slide 5: Acquisition Rationale
Acquisition Rationale 5 ACQUISITION HIGHLIGHTS AND RATIONALE • Natural extension to SWK’s existing royalty monetization business, which generates income via royalties on life science products in a mix of structures • Enteris offers opportunity to create wholly - owned portfolio of milestones and roy
Slide 6: Enteris Corporate Overview
Enteris Corporate Overview Proven Technology, Late - Stage Commercial Partnerships, and Internal Pipeline 6 ACQUISITION HIGHLIGHTS AND RATIONALE Drug Delivery Technology • Peptelligence technology allows for oral delivery of drugs that are typically injected, including peptides and BCS class II, III
Slide 7: Transaction Overview
Transaction Overview $21.5mm paid upfront to acquire 100% of Enteris’ capital stock Proceeds from Cara Therapeutics licensing agreement, which includes milestone payments and low - single digit royalties on sales o f Oral Korsuva™: ̶ Seller will receive 100% of $8.0mm upfront payment ̶ SWK will rece
Slide 8: Peptelligence Technology & Business Model Overview
PEPTELLIGENCE ® TECHNOLOGY & BUSINESS MODEL OVERVIEW
Slide 9: Peptelligence Overview
Peptelligence Overview Formulation technology that enables oral delivery of many peptide and small molecules that have poor permeability across the gut ̶ Peptides are generally not bioavailable with oral administration as they are degraded in the digestive tract Applicable to New Molecular Entities
Slide 10: Licensing Opportunity
Licensing Opportunity 10 • Oral delivery is attractive for supporting patient compliance, particularly for indications that require chronic, outpatient therapy (Insulin for example) • Franchise - like/asset light model: partners license Peptelligence and fund the substantial R&D and marketing dollar
Slide 11: Current Pharma Relationships
Current Pharma Relationships The Peptelligence technology has been licensed by three pharmaceutical partners: Enteris has material relationships with an additional four pharmaceutical companies covering multiple molecules Additionally, Enteris has a deep business development pipeline ̶ Enteris targe
Slide 12: Cara Oral Korsuva Program Overview
Cara Oral Korsuva ™ Program Overview Cara Therapeutics has licensed Enteris’ Peptelligence technology for use in its Oral Korsuva programs ̶ The oral program is based on the same novel “kappa” receptor agonist as Cara’s more advanced intravenous formulation ̶ In May 2019, announced Phase 3 results o
Slide 13: Technology Platform Economic Model
Technology Platform Economic Model Relationship begins with feasibility and development work where Peptelligence technology is tested on partner’s molecule; Ent eri s is typically paid for this work Post optimization work, Enteris generally negotiates a license agreement with partner ̶ Timing of lic
Slide 14: Manufacturing Overview
Manufacturing Overview 14 • Enteris has 23 years of manufacturing experience with a history of quality focus and regulatory compliance • Expert in handling and processing high - potency API • Current facility exceeds 30,000 square feet and can manufacture clinical trial material through Phase 2 • Fr
Slide 15: Internal Pipeline
INTERNAL PIPELINE
Slide 16: Internal Pipeline Summary
Internal Pipeline Summary Enteris has applied the Peptelligence technology to off - patent molecules that are not available in oral formulations to create p roprietary, patent - protected reformulation products In 2017 and 2018 Enteris incurred $1.4mm and $0.5mm of incremental spend on internal prod
Slide 17: Internal Pipeline Strategy
Internal Pipeline Strategy SWK may selectively fund the internal pipeline to achieve milestones to optimize out - licensing economics ̶ SWK views the internal pipeline as an extension of the licensing business model and does not currently anticipate becoming a com mercial pharmaceutical organization
Slide 18: Financials
L SWK ioxpives FINANCIALS
Slide 19: Enteris Historical Financials
Enteris Historical Financials 19 FINANCIALS Revenue averaged $5.9 million from 2016 to 2018 Revenue can be lumpy based on timing of clinical trial material manufacturing sales and license payments SWK expects Enteris will be profitable inclusive of anticipated license payments Enteris Summary GAAP F
Slide 20: Summary: Synergistic & Value Enhancing
20 Synergistic & Value Enhancing Enteris now has access to capital and resources that it can direct towards expansion and growth opportunities Enteris and SWK are aligned in the long - term vision for Peptelligence and business strategies to maximize its value Additional revenue opportunities achiev
Slide 21: Appendix
21 APPENDIX